Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC9A1 | P19634 | 7/20 | 0.55 |
| ▸ | FAAH | O00519 | 1/20 | 0.44 |
| ▸ | MGLL | Q99685 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | TUBB4A | P04350 | 1/20 | 0.39 |
| ▸ | TUBB | P07437 | 1/20 | 0.39 |
| ▸ | TUBA3C | P0DPH7 | 1/20 | 0.39 |
| ▸ | TUBA1B | P68363 | 1/20 | 0.39 |
| ▸ | TUBA4A | P68366 | 1/20 | 0.39 |
| ▸ | TUBB4B | P68371 | 1/20 | 0.39 |
| ▸ | TUBB3 | Q13509 | 1/20 | 0.39 |
| ▸ | TUBB2A | Q13885 | 1/20 | 0.39 |
| ▸ | TUBB8 | Q3ZCM7 | 1/20 | 0.39 |
| ▸ | TUBA3E | Q6PEY2 | 1/20 | 0.39 |
| ▸ | TUBA1A | Q71U36 | 1/20 | 0.39 |
| ▸ | TUBA1C | Q9BQE3 | 1/20 | 0.39 |
| ▸ | TUBB6 | Q9BUF5 | 1/20 | 0.39 |
| ▸ | TUBB2B | Q9BVA1 | 1/20 | 0.39 |
| ▸ | TUBB1 | Q9H4B7 | 1/20 | 0.39 |
| ▸ | MET | P08581 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16526236 | 0.82 | SLC9A1 (0.60) | SLC9A1FAAHMGLLALDH1A1MEN1 | |
| SCHEMBL13173782 | 0.81 | KDM1A (0.44) | SLC9A1FAAHMGLLALDH1A1TUBB4A | |
| SCHEMBL21297115 | 0.81 | SLC9A1 (0.39) | SLC9A1FAAHMGLLALDH1A1TUBB4A | |
| SCHEMBL13963730 | 0.78 | FAAH (0.45) | FAAHMGLLALDH1A1TUBB4ATUBB | |
| SCHEMBL1667917 | 0.76 | EGLN3 (0.45) | FAAHMGLLALDH1A1MEN1LMNA | |
| SCHEMBL18723049 | 0.75 | SLC9A1 (0.43) | SLC9A1FAAHMGLLALDH1A1TUBB4A | |
| SCHEMBL16522412 | 0.75 | SLC9A1 (0.43) | SLC9A1FAAHMGLL | |
| SCHEMBL14200027 | 0.75 | FAAH (0.38) | SLC9A1FAAHMGLLALDH1A1TUBB4A | |
| SCHEMBL13178731 | 0.75 | FAAH (0.38) | SLC9A1FAAHMGLLALDH1A1TUBB4A | |
| SCHEMBL8256698 | 0.75 | SLC9A1 (0.50) | SLC9A1FAAHMGLLALDH1A1TUBB4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11666594-B2 | Antibody-drug conjugates comprising a cyclic dinucleotide | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-06-06 | — | — | US | disclosed |
| US-20230121730-A1 | OXADIAZOLINE COMPOUNDS OR SALTS THEREOF, AGROHORTICULTURAL FUNGICIDES CONTAINING THE COMPOUNDS, AND METHODS OF USING THE SAME | NIHON NOHYAKU CO., LTD. (JP) | 2023-04-20 | — | — | US | disclosed |
| US-20220144838-A1 | Compounds as Inhibitors of Macrophage Migration Inhibitory Factor | Nanjing Immunophage Biotech Co., Ltd. (CN) | 2022-05-12 | — | — | US | disclosed |
| US-20210106607-A1 | ANTIBODY-DRUG CONJUGATES COMPRISING A CYCLIC DINUCLEOTIDE | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2021-04-15 | — | — | US | disclosed |
| WO-2016061527-A1 | COMPOSITIONS AND METHODS FOR TREATING CNS DISORDERS | SAGE THERAPEUTICS, INC. (US) | 2016-04-21 | — | — | WO | disclosed |
| WO-2015200677-A2 | PRMT5 INHIBITORS AND USES THEREOF | Epizyme, Inc. (US) | 2015-12-30 | — | — | WO | disclosed |
| US-20110112058-A1 | NOVEL MODULATORS OF CALCIUM RELEASE-ACTIVATED CALCIUM CHANNEL AND METHODS FOR TREATMENT OF NON-SMALL CELL LUNG CANCER | INCOZEN THERAPEUTICS PVT. LTD. (IN) | 2011-05-12 | — | — | US | disclosed |
| US-20090291971-A1 | HETEROARYL ETHERS AND PROCESSES FOR THEIR PREPARATION | WYETH (US) | 2009-11-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220144838-A1 | Compounds as Inhibitors of Macrophage Migration Inhibitory Factor | MIF, MMP12, SLC11A2 | SLC9A1 956/4885FAAH 1238/4885MGLL 442/4885 |
| US-20210106607-A1 | ANTIBODY-DRUG CONJUGATES COMPRISING A CYCLIC DINUCLEOTIDE | STING1, TLR9, CGAS | SLC9A1 858/4885FAAH 4466/4885MGLL 2998/4885 |
| US-20230121730-A1 | OXADIAZOLINE COMPOUNDS OR SALTS THEREOF, AGROHORTICULTURAL FUNGICIDES CONTAINING THE COMPOUNDS, AND METHODS OF USING THE SAME | CBR3, XDH, OXA1L | SLC9A1 570/4885FAAH 4017/4885MGLL 3841/4885 |
| US-20110112058-A1 | NOVEL MODULATORS OF CALCIUM RELEASE-ACTIVATED CALCIUM CHANNEL AND METHODS FOR TREATMENT OF NON-SMALL CELL LUNG CANCER | ORAI1, CACNB2, CACNB1 | SLC9A1 774/4885FAAH 2227/4885MGLL 2324/4885 |
| US-11666594-B2 | Antibody-drug conjugates comprising a cyclic dinucleotide | STING1, TLR9, CGAS | SLC9A1 858/4885FAAH 4466/4885MGLL 2998/4885 |
| US-20090291971-A1 | HETEROARYL ETHERS AND PROCESSES FOR THEIR PREPARATION | AHR, MALT1, ABL1 | SLC9A1 4060/4885FAAH 1951/4885MGLL 3975/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.